Koers Briacell Therapeutics Corp Toronto S.E.
Aandelen
CA10778Y1043
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 21,97 mln. 29,89 mln. 20,21 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -24 mln. -32,66 mln. -22,08 mln. | Nettowinst (verlies) 2025 * | -36 mln. -48,99 mln. -33,13 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-0,99
x | K/w-verhouding 2025 * |
-0,98
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 87,73% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
William Williams
CEO | Chief Executive Officer | 68 | 01-11-16 |
Gadi Levin
DFI | Director of Finance/CFO | 52 | 01-02-16 |
Chief Tech/Sci/R&D Officer | 53 | 01-05-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Martin Schmieg
BRD | Director/Board Member | 62 | 10-05-16 |
Marc Lustig
BRD | Director/Board Member | 51 | 31-08-21 |
Rebecca Taub
BRD | Director/Board Member | 71 | 07-03-18 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+9,42% | 115 mld. | |
+11,84% | 106 mld. | |
-1,05% | 21,96 mld. | |
-14,15% | 21,84 mld. | |
-5,29% | 19,21 mld. | |
-4,16% | 18,08 mld. | |
-38,29% | 17,71 mld. | |
+7,99% | 14,32 mld. | |
+36,24% | 12,42 mld. |